PYXS - Pyxis Oncology, Inc. News

HC Wainwright & Co. Reiterates Buy on Pyxis Oncology, Maintains $7 Price Target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Pyxis Oncology (NASDAQ:PYXS) wi

Pyxis Oncology Q2 EPS $(0.40) Misses $(0.35) Estimate

Pyxis Oncology (NASDAQ:PYXS) reported quarterly losses of $(0.40) per share which missed the analyst

Pyxis Oncology Reports Second Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clin

Updated data from the MICVO Phase 1 monotherapy study in 2L+ R/M HNSCC on track to be reported in Fa

Financial Analysis: Pyxis Oncology (NASDAQ:PYXS) and GenSight Biologics (OTCMKTS:GSGTF)

GenSight Biologics (OTCMKTS:GSGTF - Get Free Report) and Pyxis Oncology (NASDAQ: PYXS - Get Free Rep

12 Health Care Stocks Moving In Tuesday's Intraday Session

Gainers Neuronetics (NASDAQ:STIM) shares moved upwards by 34.1% to $2.91 during Tuesday's regul

This Charles Schwab Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Monday

Wall Street analysts changed outlook on top names. For full changes, see our analyst ratings page. A

Wells Fargo Initiates Coverage On Pyxis Oncology with Overweight Rating, Announces Price Target of $

Wells Fargo analyst Derek Archila initiates coverage on Pyxis Oncology (NASDAQ:PYXS) with a Overw

12 Health Care Stocks Moving In Tuesday's Intraday Session

Gainers Crinetics Pharmaceuticals (NASDAQ:CRNX) shares moved upwards by 98.7% to $83.53 during Tues

Leerink Partners Maintains Outperform on Pyxis Oncology, Lowers Price Target to $7

Leerink Partners analyst Jeffrey La Rosa maintains Pyxis Oncology (NASDAQ:PYXS) with a Outperform

Pyxis Oncology Commences ~$50M Offering Of 19.6M Common Shares At $2.551/Share

Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage company developing next-generation therapeutics

Pyxis Oncology Announces Up to $114 Million Private Placement Financing to Advance MICVO Through Key

Expected to extend cash runway into the second quarter of 2027, supporting additional follow-up for

12 Health Care Stocks Moving In Friday's Intraday Session

Gainers INVO Fertility (NASDAQ:IVF) shares moved upwards by 67.3% to $2.08 during Friday's regu

Pyxis Oncology Q1 EPS $(0.37), Inline

Pyxis Oncology (NASDAQ:PYXS) reported quarterly losses of $(0.37) per share which met the analyst co

Pyxis Oncology Reports First Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clini

Updated micvotabart pelidotin (MICVO) Phase 1 monotherapy data in 2L+ Recurrent/Metastatic Head and

Pyxis Oncology to Participate in Upcoming Investor Conferences

BOSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage compa

Pyxis Oncology Appoints Nelson Azoulay as Chief Business Officer

BOSTON, May 07, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage compa

Wedbush Initiates Coverage On Pyxis Oncology with Outperform Rating, Announces Price Target of $6

Wedbush analyst Robert Driscoll initiates coverage on Pyxis Oncology (NASDAQ:PYXS) with a Outperf

12 Health Care Stocks Moving In Wednesday's After-Market Session

Pyxis Oncology To Reveal New Preclinical Data Demonstrating Synergistic Anti-Tumor Activity In A HNS

Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage company developing next-generation therapeutics

Pyxis Oncology to Present New Preclinical Data Showing Synergistic Anti-Tumor Activity in a HNSCC mo

Mouse analog of MICVO (maMICVO) monotherapy produced dose-dependent inhibition of tumor growth in a

HC Wainwright & Co. Reiterates Buy on Pyxis Oncology, Maintains $7 Price Target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Pyxis Oncology (NASDAQ:PYXS) wi

Pyxis Oncology Q4 EPS $(0.29) Beats $(0.33) Estimate, Sales $11.038M

Pyxis Oncology (NASDAQ:PYXS) reported quarterly losses of $(0.29) per share which beat the analyst c

Pyxis Oncology Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Resu

Completed target enrollment in Phase 1 monotherapy dose expansion study of micvotabart pelidotin (MI

Pyxis Oncology (PYXS) Projected to Post Quarterly Earnings on Tuesday

Pyxis Oncology (NASDAQ: PYXS - Get Free Report) will likely be releasing its Q4 2025 results before

Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Pyxis Oncology, Inc. (NASDAQ: PYXS - Get Free Report) have earned an average recommendatio

Pyxis Oncology Announces Interim CEO Appointment and Leadership Transition to Support Strategic Focu

BOSTON, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage comp

Pyxis Oncology, Inc. (NASDAQ:PYXS) Short Interest Update

Pyxis Oncology, Inc. (NASDAQ: PYXS - Get Free Report) was the target of a large growth in short inte

Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Pyxis Oncology, Inc. (NASDAQ: PYXS - Get Free Report) has been assigned a consensus recommendation o

RBC Capital Maintains Outperform on Pyxis Oncology, Lowers Price Target to $5

RBC Capital analyst Leonid Timashev maintains Pyxis Oncology (NASDAQ:PYXS) with a Outperform and

Analysts Sound Alarm On Pyxis Oncology's Tiny Trial

Pyxis Oncology Inc. (NASDAQ: PYXS) on Thursday released preliminary data from its ongoing Phase 1 st

Analysts Sound Alarm On Pyxis Oncology's Tiny Trial

Pyxis Oncology released preliminary data from Phase 1 studies of MICVO for recurrent/metastatic head

Tesla To $444? Here Are 10 Top Analyst Forecasts For Friday

HC Wainwright & Co. Maintains Buy on Pyxis Oncology, Raises Price Target to $7

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Pyxis Oncology (NASDAQ:PYXS) wit

seekingalpha.com

Pyxis Oncology, Inc. (PYXS) Discusses Preliminary Phase 1 Data for MICVO in Recurrent and Metastatic

Nasdaq Gains Over 200 Points; US Inflation Slows To 2.7%

12 Health Care Stocks Moving In Thursday's Intraday Session

Dow Surges 400 Points; Accenture Earnings Top Views

Pyxis Oncology Shares Early Phase 1 Data For MICVO Showing Meaningful Clinical Activity In Recurrent

46% confirmed objective response rate (ORR) and 92% disease control rate (DCR) observed with MICVO a

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Pyxis Oncology Announces Positive Preliminary Phase 1 Data for Micvotabart Pelidotin (MICVO) in Recu

BOSTON, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage comp

Stephens & Co. Maintains Overweight on Pyxis Oncology, Raises Price Target to $8

Stephens & Co. analyst Sudan Loganathan maintains Pyxis Oncology (NASDAQ:PYXS) with a Overwei

Guggenheim Maintains Buy on Pyxis Oncology, Raises Price Target to $7

Guggenheim analyst Brad Canino maintains Pyxis Oncology (NASDAQ:PYXS) with a Buy and raises the p

Pyxis Oncology to Participate in Upcoming Investor Conferences

BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage comp

Pyxis Oncology Q3 EPS $(0.35) Misses $(0.34) Estimate

Pyxis Oncology (NASDAQ:PYXS) reported quarterly losses of $(0.35) per share which missed the analyst

Pyxis Oncology Provides Business Update and Reports Third Quarter 2025 Financial Results

- Preliminary data from ongoing Phase 1 clinical studies of micvotabart pelidotin (MICVO) in patien

zacks.com

Pyxis Oncology (PYXS) Upgraded to Strong Buy: Here's What You Should Know

Pyxis Oncology (PYXS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism

zacks.com

5 Small Drug Stocks to Buy as the Industry Shows Some Recovery

Innovation is at its peak in the Zacks Medical-Drugs industry. AKBA, IRWD, PYXS, CRDL and PSTV may p

Pyxis Oncology To Present Translational Data For Micvotabart Pelidotin At Upcoming Medical Meetings;

BOSTON, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage compa

12 Health Care Stocks Moving In Monday's After-Market Session